INTRINSIC VALUE WEALTH REPORT NEWSLETTER

~ Un-Common Sense In An Irrational World: We Challenge the Conventional Wisdom^TM ~

Trethera Secures $2.3M NIH Grant for Prostate Cancer – Join Investor Webinar

Trethera has been awarded a $2.3 million NIH Small Business Innovation Research (SBIR) grant to advance its lead drug candidate, TRE-515, in prostate cancer.

This funding will support preclinical studies evaluating TRE-515 in combination with radiation therapy for metastatic castration-resistant prostate cancer (mCRPC) – a disease that claims 70% of patients within five years of diagnosis.

Building on the recent FDA Fast Track designation for TRE-515 in mCRPC, this award further validates the strong scientific rationale and promising early clinical observations behind Trethera’s first-in-class dCK inhibitor. By blocking cancer cells’ ability to repair DNA damage, TRE-515 has the potential to work synergistically with radiation therapy and extend survival for patients who currently face very limited treatment options.

Read the full press release here: https://trethera.com/news/nih-grant-tre-515-radiation-prostate-cancer

About TRE-515
TRE-515 is a novel deoxycytidine kinase (dCK) inhibitor that has already demonstrated a strong safety profile and early signs of clinical benefit in an ongoing human oncology trial. With its differentiated mechanism of action, TRE-515 has the potential to reshape treatment for cancer and other serious diseases—addressing an urgent need where patients have limited options today.

Investment Opportunity

For a limited time, accredited investors may participate in Trethera’s Reg D 506(c) seed round, which remains open until September 30th. Trethera will be hosting an informational investor webinar on Tuesday, September 9, 2025 at 2 PM PT which you may register for using this link. More information can be found at trethera.com/regd or by contacting ir@trethera.com. 

~ Un-Common Sense In An Irrational World: We Challenge the Conventional Wisdom^TM ~

REVISED AND UPDATED WEALTH BUILDING EDUCATIONAL PROGRAM BEING RELEASED TODAY

We are pleased to announce that we are releasing a revised and updated edition of our popular wealth building program, which has been used by hundreds of students and others from all around the world. There is no charge for this program. It is generously supported by our sponsors. You can access the program at Build Wealth.

Saving and investing for your future is important and easy to do. Just follow the simple steps in our wealth building program, and the links under each one, to establish a powerful savings and investment program that is designed to build wealth.

The current program is based on a short handbook that I wrote in 2016 called, Four Easy and Powerful Steps to Building Wealth. To view a short video on how to get started building wealth using the earlier book, click Building Wealth in Four Steps. The current program, which is being released today, builds on this popular handbook.

To get started, click Build Wealth to begin your wealth building journey using this revised and updated edition of our approach.

~ Un-Common Sense In An Irrational World: We Challenge the Conventional Wisdom^TM ~

Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus

Trethera has been awarded a $3 million NIH Phase II SBIR grant to advance development of its first-in-class drug, TRE-515, for the treatment of lupus. This non-dilutive funding will enable regulatory-enabling studies in toxicology, pharmacology, and efficacy testing—critical steps toward initiating clinical trials in lupus patients. [Read the full press release here.]

About TRE-515
TRE-515 is a novel deoxycytidine kinase (dCK) inhibitor that has already demonstrated a strong safety profile and early signs of clinical benefit in an ongoing human oncology trial. With its differentiated mechanism of action, TRE-515 has the potential to reshape treatment for lupus and other autoimmune diseases—addressing an urgent need where patients have limited options today.

Investment Opportunity
For a limited time, accredited investors may participate in Trethera’s Reg D 506(c) seed round, which remains open until September 30th.

Trethera will host one final investor webinar on Tuesday, September 9^th at 2 PM PT. Click this link to register for the webinar.

~ Un-Common Sense In An Irrational World: We Challenge the Conventional Wisdom^TM ~

NEW VENTURE CAPITAL INVESTING ANALYSIS MODELS RELEASED

We are pleased to announce that we are releasing a new section in our Research Reports section of the Intrinsic Value Wealth Report Newsletter that covers our comprehensive approach to early-stage company analysis. This early-stage company analysis is useful in any type of early-stage venture analysis, including angel investing and venture capital investing. You can access this new material at the Research Reports link above. Be sure to click the dropdown menus at the Research Reports section for more information and models on early-stage company analysis and investing.

The material in this new section is taken from a forthcoming book on early-stage investing that I am writing called, The Intrinsic Value Wealth Report Pocket Guide to Venture Capital Investing, which is scheduled to be released in December 2005 

~ Un-Common Sense In An Irrational World: We Challenge the Conventional Wisdom^TM ~

The Second Edition of Social Entrepreneurship is on its way!

This upcoming edition, which I co-authored along with Dr. Kevin Rawls, dives even deeper into what it means to drive positive change through entrepreneurship. From stakeholder engagement and storytelling to building sustainable solutions—this book is packed with tools, strategies, and real-world examples for anyone passionate about making a difference.

I’m thrilled to share it with you soon! Whether you’re a student, educator, nonprofit leader, or mission-driven entrepreneur, this is your guide to turning vision into impact.

Stay tuned for the official launch!

~ Un-Common Sense In An Irrational World: We Challenge the Conventional Wisdom^TM ~

Trethera Seed Round Opportunity Webinar 

Trethera’s $5M Seed Round closes soon — a limited opportunity to invest in a clinical-stage biotech advancing treatments for cancer and autoimmune diseases. Following its recent FDA Fast Track designation, investor interest is accelerating and below are key details for your consideration.

Key Details:

• Round closes September 30, 2025
• Minimum investment $50K
• Valuation $29.7M

Trethera is holding a webinar regarding this opportunity today, August 14th, at 1 pm Pacific Time. You can access the webinar at Invitation Link: https://us06web.zoom.us/webinar/register/7017551264754/WN_uGyv3wd6SXesum17RW9ohQ

You can access the complete webinar invitation on our Sponsored Research page for Trethera here.

About Trethera

Trethera is a clinical stage, privately held, biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally administered capsule twice designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth, and certain autoimmune diseases might also respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients.

~ Un-Common Sense In An Irrational World: We Challenge the Conventional Wisdom^TM ~

ECONOMIC REPORTS: July Inflation Held Steady at a 2.7% Rate

Inflation held steady in July at a 2.7% rate, as reported in the Wall Street Journal this morning. This was despite tariff increases which affected some consumer prices. A Fed rate cut is still possible next month.

Please see the inflation chart we posted in our Chart section of the Intrinsic Value Wealth Report Newsletter.

~ Un-Common Sense In An Irrational World: We Challenge the Conventional Wisdom^TM ~

CASSANDRA BILLIONAIRE HEDGE FUND STOCK SELECTION MODEL RE-RELEASED

We are pleased to announce that we are re-releasing our popular Cassandra Billionaire Hedge Fund Stock Selection Model. The Cassandra Billionaire Hedge Fund Stock Selection Model is a listing of portfolio holdings held by some of the top hedge fund managers in the world. We have taken this listing of hedge fund holdings and run it through the Cassandra Stock Selection Model. We believe we can add significant value by viewing these holdings through the lens of our proprietary model which seeks to find companies to invest in that are: (1) good companies; (2) that are growing; and, (3) for which we are paying a reasonable or better price.

The Cassandra Stock Selection Model spreadsheet and notes for this Investing with the Billionaires section of the Intrinsic Value Wealth Report Newsletter can be accessed through the Billionaire Portfolios dropdown menus.